Alopecia Treatments in Breastfeeding: Safety and Clinical Considerations

Early diagnosis and a multidisciplinary approach are crucial for managing Frontal Fibrosing Alopecia.

In this case series, low-dose oral metformin was associated with improvements in symptoms and gene expression changes in Black female patients with treatment-resistant central centrifugal cicatricial alopecia, suggesting a potential therapeutic role for metformin in managing this condition.

This study found that platelet-rich plasma therapy may improve symptoms and quality of life in adults with moderate to severe atopic dermatitis, although standardized protocols for its preparation need further study.

In this article, a case report examines the use of topical metformin 10% cream for treating central centrifugal cicatricial alopecia, contributing to existing literature on potential treatments for this condition.

This review article examines the current understanding of frontal fibrosing alopecia, noting its prevalence in different demographics and the roles of genetic and environmental factors in its pathogenesis, while highlighting that treatment approaches remain varied and lack standardization.

This article reviews DPCP's use as a topical immunotherapy for alopecia areata and discusses its suggested mechanism, but reports no clinical results.

This study found that oral isotretinoin significantly reduced symptoms in nearly 90% of patients with frontal fibrosing alopecia, affecting both facial papules and hair loss.

This consensus statement outlines a treatment algorithm for alopecia areata, detailing systemic treatment indications and options, including EMA-approved medications baricitinib and ritlecitinib for severe cases, as well as other off-label treatments and adjuvant therapies like oral minoxidil.

This article suggests considering biologics to stabilize inflammation in moderate to severe folliculitis decalvans, although it reports no new clinical results.

JAK inhibitors and platelet-rich plasma show promise for treating alopecia areata.

This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.

Alopecia Areata affects 2% globally, with treatments like essential oils, garlic, and JAK inhibitors showing promise, but more research is needed.

This study reviewed the safety of JAK inhibitors for alopecia areata, finding that common side effects included headache and acne, with varying risks for respiratory infections and no increased risk of serious adverse events.

This article reviews treatment options for female-pattern hair loss, noting the limited evidence for most therapies and emphasizing that topical minoxidil remains the only well-supported option despite a significant non-response rate.

In this study, low-dose naltrexone significantly reduced erythema in patients with frontal fibrosing alopecia and lichen planopilaris after one year, but no significant improvements were seen in other symptoms.

This review discusses current treatments for cicatricial alopecia focused on reducing inflammation to prevent further hair loss and suggests auxiliary therapies to improve the appearance of remaining hair, without reporting new clinical results.

In this study, the authors reported that oral dutasteride at 0.5 mg/day showed a probable greater efficacy in treating male androgenetic alopecia compared to finasteride and minoxidil, but it may cause sexual dysfunction and neuropsychiatric side effects.

This abstract outlines a guide reviewing both FDA-approved and off-label therapies for androgenetic alopecia and proposes treatment algorithms based on scientific research, highlighting a gap in common treatments for this prevalent condition.

Adalimumab improved folliculitis decalvans in most patients.

This review examines the definition, classification, mechanism, clinical efficacy for hair regrowth, and potential adverse effects of platelet rich plasma, but does not present new experimental results.

This review discusses treatment options for androgenetic alopecia, highlighting the need for personalized, evidence-based approaches but reports no new clinical results.

This study observed that in children who unintentionally consumed high-dose oral minoxidil, 65% developed hypertrichosis, predominantly on the face, and 15% experienced mild systemic side effects.

This review examines recent literature on isotretinoin's teratogenic effects in both fertile females and males, analyzing its role in causing congenital malformations but provides no new clinical results.

In this study, low-dose oral minoxidil for hair loss was associated with infrequent systemic adverse effects, and only 1.7% of patients discontinued treatment due to these effects.

This correspondence discusses clascoterone as a potential new treatment for androgenetic alopecia but reports no clinical results.

This article discusses the staging of central centrifugal cicatricial alopecia in women of African descent and reports no new clinical results.

This review discusses female androgenetic alopecia, highlighting its diagnostic challenges and management strategies, but it reports no new results.

Clascoterone safely promotes hair growth similar to minoxidil.

This review assessed the effectiveness of various treatments for frontal fibrosing alopecia and found that intralesional steroids and 5α-reductase inhibitors showed the most positive outcomes in slowing or halting hair loss, though the lack of placebo-controlled studies and consistent outcome measures limits definitive conclusions.

This consensus statement outlines a treatment algorithm for alopecia areata, discussing when to consider systemic treatment and how to assess outcomes, without providing new clinical results.

This study reported that a 10-week course of clindamycin and rifampicin was commonly used for treating folliculitis decalvans but the evidence on its efficacy remains inconclusive due to the low quality of available studies.

This review summarizes existing evidence on the efficacy and safety of JAK inhibitors for treating alopecia areata and emphasizes the need for improved topical formulations.

This guideline review by the European Dermatology Forum evaluates current treatments for androgenetic alopecia but reports no new research findings, aiming to assist dermatologists in selecting safe and effective therapies.

According to this study, systemic retinoids, specifically oral isotretinoin and acitretin, were more effective than finasteride in stabilizing the frontal hairline in female patients with frontal fibrosing alopecia, achieving treatment goals in over 70% of cases.

This review discusses the adverse events associated with 5-alpha reductase inhibitors, finding them generally well-tolerated but noting potential risks like sexual side effects and psychological effects in men, and sparse data on use in women.

This study found that 308-nm excimer laser therapy improved hair diameter in alopecia areata patients, as shown by photographic assessments and a side-by-side comparison with control patches.

In this study, the 308-nm excimer lamp was reported to be a safe alternative treatment for alopecia areata, with a 41.1% overall response rate and a 50% response rate in severe cases.

This review discusses the clinical use of anti-androgen medications and highlights emerging evidence supporting plant-derived anti-androgens like spearmint tea for managing PCOS, but reports no new clinical results.

This review examines topical immunotherapy for severe alopecia areata, noting that diphencyprone and squaric acid dibutylester are non-mutagenic options with similar efficacy but different practical considerations, and reports no new clinical results.

Minoxidil in breast milk may harm nursing infants.